Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer

Published:2017-01 Issue:1 Volume:12 Page:145-151
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ou Sai-Hong Ignatius,Govindan Ramaswamy,Eaton Keith D.,Otterson Gregory A.,Gutierrez Martin E.,Mita Alain C.,Argiris Athanassios,Brega Nicoletta M.,Usari Tiziana,Tan Weiwei,Ho Steffan N.,Robert Francisco

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference10 articles.

1. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors;Sequist;Sci Transl Med,2011

2. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements;Kazandjian;Oncologist,2014

3. Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancer;Kazandjian;Oncologist,2016

4. Activity of crizotinib (PF02341066), a dual mesenchymal epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification;Ou;J Thorac Oncol,2011

5. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC);Camidge;J Clin Oncol,2014

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the potential of bispecific ADCs for targeted cancer therapy;Frontiers of Medicine;2024-07-23

2. The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC;JTO Clinical and Research Reports;2024-02

3. Ocular Surface Side Effects of Novel Anticancer Drugs;Cancers;2024-01-13

4. A Systematic Review of Mesenchymal Epithelial Transition Factor (MET) and Its Impact in the Development and Treatment of Non-Small-Cell Lung Cancer;Cancers;2023-07-27

5. Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer;British Journal of Cancer;2023-04-14